Sponsored Post

XPhyto Therapeutics USA (XPHYF) Canada (XPHY.CN) One-Upping Competition with CV-19 Diagnostic Testing

Plus, Here’s How XPhyto Therapeutics is Revolutionizing Drug Delivery

News Release 9-22-2020:

XPhyto Announces Update on Oral Thin Film Drug Delivery Programs

With CV-19 tests under big demand, investors have made a fortune.(1)

Since March 2020:

However, with the virus showing no signs of slowing, the world needs many more tests.

And until a vaccine is deemed safe and effective, we can only hope to manage its spread with the help of COVID-19 tests in hospitals, homes, sports events, airports, schools.

Along the way, it could create a massive $10 billion market opportunity(2) with companies like XPhyto Therapeutics USA (XPHYF) Canada (XPHY.CN) racing to meet demand and quickly nearing commercialization of its CV-19 test that uses saliva and nasal-throat swabs.

That’s big news.

After all, “Filling a vial with saliva is also faster and requires less contact with other people, which is why labs around the world are investigating COVID-19 diagnostic tests that trade swabs for spit,” says Discover.(3)

The world needs millions of tests – and fast.

But there’s a problem. Test demand is straining supply.(4)

So much so, the U.S. Congress may soon consider legislation to ensure there are enough tests to go around. In fact, according to former U.S. FDA Commissioner Scott Gottlieb, and Dr. Mark McClellan, director of the Duke-Margolis Center for Health Policy:

“Washington could contract with commercial labs and point-of-care test manufacturers to develop and maintain diagnostic capacity for a crisis. Think of it as part of the national stockpile. Under such contracts, companies would build more labs and sprinkle them throughout the country so capacity could be available wherever it’s needed.”(5)

This is where XPhyto Therapeutics comes into play.

The company just announced that its rapid detection COVID-19 technology was validated in preliminary testing. In collaboration with German medical diagnostics firm, 3a-Diagnostics GmbH, the two confirmed successful function of its novel and proprietary COVID-19 (SARS-CoV-2) RNA probes and its universal coronavirus RNA probes in prototype lateral flow assay testing.

“XPhyto and 3a are working to develop and commercialize a real-time, low-cost and easy-to-use oral screening test to concurrently detect COVID-19 and non-COVID-19 corona-viruses. 3a is particularly focused on detection of viruses during the early stages of infection when patients are highly contagious and often asymptomatic. The LFA is designed for use with saliva samples and is also expected to function effectively using test solutions from throat and nasal swabs.”

“We believe that a low-cost, portable and easy to use screening tool that provides rapid on-the-spot results would be a disruptive tool in the fight against pandemic threats,” said Hugh Rogers, CEO of XPhyto. “We see an enormous global market opportunity that includes individual households, schools, hospitals, public transportation, airports and border services as well as many private employers.”

That’s reason No. 1 to pay close attention to XPHYF stock.

Here’s reason No. 2.

This is How XPhyto Therapeutics USA (XPHYF) Canada (XPHY.CN) is Revolutionizing Drug Delivery

Effective drug delivery is a significant problem around the world.

In fact, according to the World Health Organization, medication adherence is as low as 50%.

“Nonadherence can account for up to 50% of treatment failures, around 125,000 deaths, and up to 25% of hospitalizations each year in the United States.”(6)

People around the world aren’t taking their medication, even though many of us spend top dollar for medications. Billions, even trillions of dollars are being spent on medications that aren’t being used. One of the top reasons for that is drug delivery.

Some folks can’t open the medication bottle. Some can’t swallow pills or capsules.

That’s where XPhyto Therapeutics can help with its revolutionary “thin film” technology that could potentially help millions of patients that don’t take their medications regularly.

In fact, Vektor, a wholly-owned subsidiary of XPhyto has developed such a product.

Using its thin film technology, Vektor created an oral dispersal film that can be dosed with exact amounts of medication, which melt in your mouth, and go straight to the bloodstream.

Plus, such “thin film” technology may be able to cut back on dosing issues.

The other major issue is potential overdosing.

Most parents give the wrong dose of liquid medication, says The New York Times.(7)

In some cases, twice as much as instructed.

In a study published in the journal, Pediatrics, it randomly assigned 2,110 parents to one of five pairings of the many possible combinations of tools and label instructions.

“In nine trials, 84.4 percent of the parents made at least one dosing error, and more than 68 percent of the errors were overdoses. About 21 percent of parents at least once measured out more than twice the proper dose. Smaller doses produced more errors. When the dose was 2.5 milliliters, there were more than four times as many errors as when it was 5 milliliters.”(7)

It’s why “many pharmaceutical companies are switching their products from tablets to fast dissolving oral thin films,” says the National Library of Medicine.(8)

“Films have all the advantages of tablets (precise dosage, easy administration) and those of liquid dosage forms (easy swallowing, rapid bioavailability). Statistics have shown that four out of five patients prefer orally disintegrating dosage forms over conventional solid oral dosages forms.”(8)

One of the top ways XPhyto Therapeutics is helping is with its development of sublingual CBD thin film that’s easy to take, and can deliver a larger portion of active compound per dose than by swallowing CBD.

Better, the company is producing oral wafers, infused with an approved therapeutic, a CBD product for the treatment of epilepsy. Helping, the U.S. Drug Enforcement Agency having just taken the CBD drug Epidiolex off the controlled substances list.

One of the top markets XPhyto can help treat is the $16.5 billion epilepsy treatment market.

At the moment, analysts at JP Morgan say Epidiolex sales could reach $1 billion by 2023.(9)

Bank of America says annual sales could hit $2.5 billion by 2027.(10)

But there’s a problem.

Epidiolex is administered orally as a liquid taken with a 5 mL or 1 mL oral syringe, which leaves it open to potential dosing errors mentioned above.(11)

However, with its thin film CBD technology, XPhyto Therapeutics could be a game-changer in the $16.5 billion epilepsy treatment market.

Even better, based on initial dissolution testing using XPhyto’s proprietary thin film drug delivery system, the company’s oral delivery system may yield as much as a 10-to-20-times increase in bioavailability of CBD over existing oil delivery methods.

XPhyto CEO Hugh Rogers says, “An efficient and well-defined dosage form is the future of cannabis-based medicine. High bioavailability with controlled and reproducible delivery is critical. Our initial results suggest significant potential timing and efficiency advantages over conventional delivery methods.”

The potential solution for drug delivery is substantial.

Reason No. 3 – Charts Don’t Lie

As it nears commercialization of its CV-19 test, and revolutionizes the drug delivery market, shares of XPHYF have been explosive.

Since bottoming out at $1.74 in June 2020, the stock rallied to a recent all-time high of $2.43.

Nowadays, with a solid set of catalysts just around the corner, it wouldn’t be surprising to see this XPHYF stock begin its next leg up, especially with its new listing on the OTCQB Venture.

The Top Reasons

to Consider XPhyto Therapeutics USA (XPHYF) Canada (XPHY.CN)

1) One, the company is racing to meet COVID-19 diagnostic test kit demand. Until a vaccine is deemed safe and effective, we can only hope to manage its spread with the help of COVID-19 tests in hospitals, homes, sports events, airports, schools. Along the way, it could create a massive $10 billion market opportunity.

2) Two, the company could revolutionize drug delivery with its “thin film” dissolvable tabs. In fact, with its thin film CBD technology, XPhyto Therapeutics could be a game-changer in the $16.5 billion epilepsy treatment market.

3) Three, based on initial dissolution testing using XPhyto’s proprietary thin film drug delivery system, the company’s oral delivery system may yield as much as a 10-to-20-time increase in bioavailability of CBD over existing oil delivery methods. That news alone could give GW Pharmaceuticals’ Epidiolex a run for its money.

 

Source 1: https://www.mining.com/cobalt-nickel-other-battery-metals-face-supply-crunch-by-2020s-woodmac/

Source 2: https://www.tirebusiness.com/automotive/electric-vehicle-sales-growing-faster-expected

Source 3: https://energynews.us/2020/08/26/midwest/commentary-how-electrifying-michigan-fleet-cars-could-spur-evs-in-a-post-covid-world/

Source 4: https://www.businessinsider.com/most-cars-electric-doe-report-2016-2

Source 5: https://www.corporateknights.com/reports/future-40/albertas-lithium-laced-oil-fields-can-fuel-electric-vehicle-revolution-15943950/

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 8/4/20 and ending on 8/31/20 to publicly disseminate information about (XPHYF) via digital communications. We have been paid one hundred thousand USD via bank wire transfer. Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 9/1/20 and ending on 9/14/20 to publicly disseminate information about (XPHYF) via digital communications. We have been paid an additional twenty five thousand USD via bank wire transfer. We own zero shares of (XPHYF). To date we have been paid one hundred twenty five thousand USD via bank wire transfer to disseminate information about (XPHYF) via digital communications.

Disclaimer

Privacy Policy

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gain Access & Get Instant Breaking News Before The Crowd!